These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27619843)

  • 21. Regional regulators in health care service under quality competition: A game theoretical model.
    Bisceglia M; Cellini R; Grilli L
    Health Econ; 2018 Nov; 27(11):1821-1842. PubMed ID: 30044027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crucial questions for physiotherapy in Finland.
    Paatero H; Holma T; Leisti S
    Int J Technol Assess Health Care; 1992; 8(1):20-5. PubMed ID: 1601589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hospital prices and market structure in the hospital and insurance industries.
    Moriya AS; Vogt WB; Gaynor M
    Health Econ Policy Law; 2010 Oct; 5(4):459-79. PubMed ID: 20478106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imperfect information in a quality-competitive hospital market.
    Gravelle H; Sivey P
    J Health Econ; 2010 Jul; 29(4):524-35. PubMed ID: 20573413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Marketwide Price Transparency Suggests Significant Opportunities For Value-Based Purchasing.
    Sinaiko AD; Kakani P; Rosenthal MB
    Health Aff (Millwood); 2019 Sep; 38(9):1514-1522. PubMed ID: 31479358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physician practice competition and prices paid by private insurers for office visits.
    Baker LC; Bundorf MK; Royalty AB; Levin Z
    JAMA; 2014 Oct 22-29; 312(16):1653-62. PubMed ID: 25335147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Public health care providers and market competition: the case of Finnish occupational health services.
    Kankaanpää E; Linnosmaa I; Valtonen H
    Eur J Health Econ; 2011 Feb; 12(1):3-16. PubMed ID: 20111884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Competition in health insurance markets: limitations of current measures for policy analysis.
    Scanlon DP; Chernew M; Swaminathan S; Lee W
    Med Care Res Rev; 2006 Dec; 63(6 Suppl):37S-55S. PubMed ID: 17099129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship among cost, quality, and competition: an analysis of obstetrics services in Missouri hospitals.
    Skelton AG
    J Health Care Finance; 1997; 24(1):30-44. PubMed ID: 9327357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching health insurers: the role of price, quality and consumer information search.
    Boonen LH; Laske-Aldershof T; Schut FT
    Eur J Health Econ; 2016 Apr; 17(3):339-53. PubMed ID: 25820635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing competition in hospital care markets: the importance of accounting for quality differentiation.
    Tay A
    Rand J Econ; 2003; 34(4):786-814. PubMed ID: 15025031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Price competition in the Chinese pharmaceutical market.
    Wang YR
    Int J Health Care Finance Econ; 2006 Jun; 6(2):119-29. PubMed ID: 16783505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors affecting the entry of for-profit providers into a price regulated market for formal long-term care services: a case study from Japan.
    Tokunaga M; Hashimoto H
    Soc Sci Med; 2013 Jan; 76(1):143-9. PubMed ID: 23182594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is healthy competition healthy? New evidence of the impact of hospital competition.
    Gift TL; Arnould R; DeBrock L
    Inquiry; 2002; 39(1):45-55. PubMed ID: 12067074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of injecting price competition into the hospital market: the case of preferred provider organizations.
    Dranove D; Satterthwaite M; Sindelar J
    Inquiry; 1986; 23(4):419-31. PubMed ID: 2947862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Price elasticities in the German Statutory Health Insurance market before and after the health care reform of 2009.
    Pendzialek JB; Danner M; Simic D; Stock S
    Health Policy; 2015 May; 119(5):654-63. PubMed ID: 25670009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Price-cost margin in the pharmaceutical industry. Empirical evidence from Finland.
    Linnosmaa I; Hermans R; Hallinen T
    Eur J Health Econ; 2004 Jun; 5(2):122-8. PubMed ID: 15452748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Entry regulation and the effect of public reporting: Evidence from Home Health Compare.
    Wu B; Jung J; Kim H; Polsky D
    Health Econ; 2019 Apr; 28(4):492-516. PubMed ID: 30689246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterogeneous Effects of a Nonlinear Price Schedule for Outpatient Care.
    Farbmacher H; Ihle P; Schubert I; Winter J; Wuppermann A
    Health Econ; 2017 Oct; 26(10):1234-1248. PubMed ID: 27492210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Constrained competition in parallel drug importation: the case of simvastatin in Germany, the Netherlands, and the United Kingdom].
    Costa-Font J; Kanavos P
    Gac Sanit; 2007; 21(1):53-9. PubMed ID: 17306187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.